PHASE II STUDY OF IMATINIB MESYLATE AS THERAPY FOR PATIENTS WITH SYSTEMIC MASTOCYTOSIS

Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003–2005 in phase II clinical trial with ima...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Vega-Ruiz, Arturo, Cortes, Jorge E., Sever, Matjaz, Manshouri, Taghi, Quintás-Cardama, Alfonso, Luthra, Raja, Kantarjian, Hagop M., Verstovsek, Srdan
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2009
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184059/
https://ncbi.nlm.nih.gov/pubmed/19193436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.12.020
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items